Mechanism of action of antipsychotic drugs: From dopamine D2 receptor antagonism to glutamate NMDA facilitation
References (75)
- et al.
CNS stimulants as tools in the study of schizophrenia
Trends Neurosci
(1984) - et al.
The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
Neuropsychopharmacology
(1999) - et al.
Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats
Brain Res Bull.
(1996) - et al.
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia
Biol Psychiatry.
(2000) - et al.
Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients
Lancet
(1995) - et al.
Presynaptic dopaminergic function in the striatum of schizophrenic patients
Schizophr Res.
(1997) - et al.
Depressive symptoms and presynaptic dopamine function in neurolepticnaive schizophrenia
Schizophr Res.
(1999) - et al.
Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by l-(beta-11C) DOPA and PET
Biol Psychiatry
(1999) - et al.
Increased dopamine transmission in schizophrenia: Relationship to illness phases
Biol Psychiatry
(1999) The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies
Brain Res Brain Res Rev
(2000)
Subanesthetic doses of ketamine stimulate psychosis in schizophrenia
Neuropsychopharmacology
(1995)
Effects of ketamine in normal and schizophrenic volunteers
Neuropsychopharmacology
(2001)
D-serine added to antipsychotics for the treatment of schizophrenia
Biol Psychiatry
(1998)
Glutamate receptor expression in schizophrenic brain
Brain Res Brain Res Rev
(2000)
Molecular aspects of glutamate dysregulation: Implications for schizophrenia and its treatment
Pharmacol Ther
(2003)
Neurotransmitter interactions in schizophrenia—therapeutic implications
Biol Psychiatry
(1999)
Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum
Prog Neurobiol
(1994)
Dopamine-mediated regulation of striatal neuronal and network interactions
Trends Neurosci.
(2000)
Dopamine D1 and D2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-D-aspartic acid
Eur J Pharmacol.
(1994)
Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain
Acta Pharmacol Toxicol (Copenh)
(1963)
Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons
Science
(1975)
Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
Science
(1976)
Provocative tests with psychostimulant drugs in schizophrenia
Psychopharmacology (Berl)
(1987)
Glutamate receptor dysfunction and schizophrenia
Arch Gen Psychiatry
(1995)
Recent advances in the phencyclidine model of schizophrenia
Am J Psychiatry
(1991)
Glutamate pharmacology and the treatment of schizophrenia: Current status and future directions
Int Clin Psychopharmacol.
(1995)
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia
Am J Psychiatry.
(2001)
Elevated dopa decarboxylase activity in living brain of patients with psychosis
Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia
Nat Neurosci
(2002)
Presynaptic dopaminergic dysfunction in schizophrenia: A positron emission tomographic [18F]fluorodopa study
Arch Gen Psychiatry
(2004)
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort
Am J Psychiatry.
(1998)
Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
Increased baseline occupancy of D2 receptors by dopamine in schizophrenia
Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
Arch Gen Psychiatry.
(1994)
Amelioration of negative symptoms in schizophrenia by glycine
Am J Psychiatry
(1994)
Cited by (0)
Copyright © 2005 Published by Elsevier Inc.